That CancerVax(CNVX) failed phase 3 trial on melanoma caused the company to lose $US88 million market cap yesterday . Nice to be in a co like Solbec where the only question is not if it kills cancer , but which cancer does it kill best , for target selection in the upcomming phase 2 trials . Even with the failed trial CNVX market cap is 5 times Solbecs .
Cheers
SBP
solbec pharmaceuticals limited
That CancerVax(CNVX) failed phase 3 trial on melanoma caused the...
Add to My Watchlist
What is My Watchlist?